Progress of the Pan-American Exposition
نویسندگان
چکیده
منابع مشابه
john steinbeck: friend of the american common man
in his last years of life americans had almost forgotton steinbeck, and those who had not, occasionally criticized him for supporting and praising the u. s. military intervention in the vietnam war. althought ateinbeck incorporates different themes into his works, each one bears many signs of his concern and sympathy for america and the american common people in particular. steinbecks to a god ...
15 صفحه اولPan American Climate Studies
Over its ten-year lifetime, the Tropical OceanGlobal Atmosphere (TOGA) program (1985-1995) made major strides toward understanding the El Niño/Southern Oscillation (ENSO) phenomenon, which impacts surface air temperature and rainfall over many regions of the globe. In particular, TOGA demonstrated the feasibility of operational seasonalto-interannual climate prediction of equatorial Pacific sea...
متن کاملAmerican society of hematology: 56th annual meeting and exposition.
Key research focused on mantle cell lymphoma, Hodgkin's lymphoma, human immunodeficiency virus-related lymphoma, myelodysplastic syndrome, and myelofibrosis.
متن کاملAmerican society of hypertension: 25th annual scientific meeting and exposition.
17.9 mm Hg. In patients with BMIs lower than 30 kg/m2, systolic BP was reduced by 30.6 mm Hg and diastolic BP was reduced by 20.6 mm Hg. The percentages of patients receiving combination therapy who achieved BP goals at the eighth week also tended to be greater if the BMI was below 30 kg/m2 (41%–55%) than if the BMI was higher (28%–52%). “Olmesartan should reduce the edema associated with amlod...
متن کاملAmerican society of hematology, 52nd annual meeting and exposition.
ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials in Newly Diagnosed Patients) is a global, multicenter, randomized phase 3 study. Conducted at 217 centers in 35 countries, this study is comparing nilotinib (Tasigna, Novartis) with imatinib (Gleevec, Novartis) in patients with newly diagnosed CML–CP. At 24 months, among patients receiving nilotinib 300 mg twice daily (n = 282...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific American
سال: 1900
ISSN: 0036-8733
DOI: 10.1038/scientificamerican11241900-329